U.S. pharma giant copyright scrapped two experimental weight loss products past calendar year—a at the time-daily pill, lotiglipron, as a result of elevated liver enzymes along with a twice-day-to-day tablet, danuglipron, as a consequence of strong side effects—but CEO Albert Bourla has stated the company is set to “Engage in and get” insid